Main article

BD Diagnostics, a segment of Becton, Dickinson, and Co. (Franklin Lakes, N.J.), has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to utilize two of its amplified DNA assays for Chlamydia trachomatis and Neisseria gonorrhoeae with samples collected during routine liquid-based Pap testing for cervical cancer screening.

Subscribers: click here for the full story

Non-Subscribers: click here to subscribe

January 2010 - Table of Contents

DTTR January 2010 (Full PDF Issue)

H1N1 Flu Testing Volume Down 75% Since October

Becton Dickinson Completes $275 Million Acquisition of HandyLab

deCODE Genetics Files for Bankruptcy

FDA Authorizes Emergency Use of H1N1 Flu Tests from Roche, DxNA, TessArae

Gen-Probe Receives FDA Clearance for Prodesse Parainfluenza Test

Medicare Finalizes Decision to Cover HIV Screening

Inside the Diagnostics Industry: H1N1 Virus Activity and Testing Volumes Down From Fall High, but Labs Remain Vigilant

Lab Test Volumes Climb in 2009, G-2 Survey Finds

Cystic Fibrosis Screening Linked to Decreased Disease Incidence

Life Technologies Completes Purchase of BioTrove

Clarient Acquires Applied Genomics

Screening Test Can Identify Newborns With Blood Disorder, JAMA Study Finds

Genetic Findings May Translate to New Test for Lung Cancer

BD Receives Expanded Clearance for STD Tests

IVD Stocks Gain 6%; OraSure Up 20% on Medicare Decision to Cover HIV Testing

G2 Insider (January 2010)